Rani developed a proprietary platform, RaniPill, designed to provide a pill-based alternative to intravenous or subcutaneous administration of biologics.
Rani Therapeutics has raised $53 million to support manufacturing as it gears up for clinical trials of its Rani robotic pill. New investors like GeneScience Pharmaceuticals and Shire (NSDQ:SHPG) joined existing investors like Alphabet’s GV, Novartis (NYSE:NVS) and AstraZeneca (NYSE:AZN). Rani has now raised $142 million in total funding. Rani is an InCube Lab spin-out…
